Enzyme News and Research

RSS

Celtaxsys announces acquisition of CTX-4430 from Estrellita

Celtaxsys, Inc. a privately held biotechnology company, announced today that it has acquired CTX-4430 (formerly EP-501), a clinical stage drug candidate that inhibits the pro-inflammatory enzyme Leukotriene A4 Hydrolase (LTA4H), from Estrellita Pharmaceuticals, Inc.

6 Jan 2012

Combination of cancer drugs shows promise against Pompe disease

Kids with Pompe disease fail because of a missing enzyme, GAA, that leads to dangerous sugar build-up, which affects muscles and movement. An enzyme replacement treatment pioneered at Duke University has saved many lives, but some children with Pompe disease produce an immune reaction that blocks the benefits of the life-saving enzyme treatment.

6 Jan 2012

Positive preliminary results from Alnylam's Phase I ALN-PCS trial on severe hypercholesterolemia

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today the achievement of positive preliminary results from its ongoing clinical trial of ALN-PCS, an RNAi therapeutic targeting PCSK9 for the treatment of severe hypercholesterolemia.

5 Jan 2012

Scientists determine structure of endomannosidase enzyme

Scientists have determined the structure of the enzyme endomannosidase, significantly advancing our understanding of how a group of devastating human viruses including HIV and Hepatitis C hijack human enzymes to reproduce and cause disease.

4 Jan 2012

$Viamet commences VT-464 Phase 1/2 trial in castration-refractory prostate cancer$

Viamet commences VT-464 Phase 1/2 trial in castration-refractory prostate cancer

Viamet Pharmaceuticals, Inc., announced today that dosing has begun in a Phase 1/2 clinical trial of VT-464, an oral, potent and lyase-selective CYP17 inhibitor for the treatment of castration-refractory prostate cancer.

4 Jan 2012

Losartan may help prevent smoking-related COPD

Working with mice, scientists at Johns Hopkins have successfully used a commonly prescribed blood pressure medicine, losartan (Cozaar), to prevent almost all of the lung damage caused from two months of exposure to cigarette smoke. The treatment specifically targeted lung tissue breakdown, airway wall thickening, inflammation and lung over-expansion.

4 Jan 2012

Non-invasive test for early detection of fetal gender

A new research study published in the January 2012 edition of The FASEB Journal describes findings that could lead to a non-invasive test that would let expecting mothers know the sex of their baby as early as the first trimester.

4 Jan 2012

MRC-funded study to explore pancreatic cancer

A promising line of attack against pancreatitis and pancreatic cancer is to be explored further at Cardiff University, thanks to substantial new funding from the Medical Research Council.

4 Jan 2012

Hydrogen sulfide decreases manufacture of kidney scarring matrix proteins

Hydrogen sulfide, a gas notorious for its rotten-egg smell, may have redeeming qualities after all. It reduces high glucose-induced production of scarring proteins in kidney cells, researchers from The University of Texas Health Science Center San Antonio report in the Journal of Biological Chemistry.

4 Jan 2012

Origin of osteoporosis could be directly linked to manganese depletion

The loss of manganese could mean that calcium does not stick to bones and could cause osteoporosis. This is the new theory put forward by researchers at the University of Castilla-La Mancha (UCLM) in Spain after studying deer antlers.

3 Jan 2012

Alexion to acquire 100% of capital stock of Enobia

Alexion Pharmaceuticals, Inc. and Enobia Pharma Corp. today announced that the companies have signed a definitive agreement under which Alexion will acquire 100% of the capital stock of Enobia.

29 Dec 2011

Meta-analysis does not find significant association between CYP2C19 genotype and cardiovascular events

Although the U.S. Food and Drug Administration (FDA) has recommended that a certain type of genetic testing (for the genotype CYP2C19) be considered before prescribing the drug clopidogrel to identify individuals who may be less responsive to the medication, a review and analysis of previous studies did not find an overall significant association between the CYP2C19 genotype and cardiovascular events.

28 Dec 2011

Synthetic drugs treat Crohn's disease in mice

A team of Weizmann Institute scientists has turned the tables on an autoimmune disease. In such diseases, including Crohn's and rheumatoid arthritis, the immune system mistakenly attacks the body's tissues. But the scientists managed to trick the immune systems of mice into targeting one of the body's players in autoimmune processes, an enzyme known as MMP9.

26 Dec 2011

Biologists develop radar to track ADAR's RNA editing activity in neurons

To track what they can't see, pilots look to the green glow of the radar screen. Now biologists monitoring gene expression, individual variation, and disease have a glowing green indicator of their own: Brown University biologists have developed a "radar" for tracking ADAR, a crucial enzyme for editing RNA in the nervous system.

26 Dec 2011

Researchers report how sildenafil can alleviate heart problems

How sildenafil, the active ingredient in Viagra, can alleviate heart problems is reported by Bochum's researchers in cooperation with colleagues from the Mayo Clinic in Rochester (Minnesota) in the journal Circulation.

26 Dec 2011

LANL's top 10 science stories of 2011

Los Alamos National Laboratory's top 10 science stories of 2011 illustrate the broad variety of scientific excellence that's the hallmark of the Laboratory. This year's stories include alternative energy research, world record magnetic fields, disease tracking, the study of Mars, climate change, fuel cells, solar wind, and magnetic reconnection.

26 Dec 2011